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Abstract 
 
Background: Impulsive drive for immediate reward (IDIR) and 
delay aversion are dissociable elements of the preference for 
immediate over delayed rewards seen in Attention 
Deficit/Hyperactivity Disorder (ADHD). We hypothesized that 
IDIR would be associated with dopamine regulating genes and 
delay aversion with serotonin regulating genes. 
Methods: IDIR and delay aversion were measured in 459 male 
children and adolescents (328 ADHD and 131 unaffected 
siblings) using a laboratory choice task. The sample was 
genotyped for the 5HTT (SLC6A4) promoter 5-HTTLPR polymorphism 
and a DAT1 (SLC6A3) 40-base pair VNTR located in the 3`-
untranslated region of the gene. 
Results: There was no effect of DAT1 on IDIR. As predicted 5-
HTTLPR s-allele carriers were more delay averse. This effect 
was driven by the s/l genotype in the ADHD group. These 
results were not altered by taking account of the rs25531 A/G 
SNP and were independent of age, IQ and ODD symptoms.  
Conclusions: The results support the genetic distinctiveness 
of IDIR and delay aversion in ADHD and implicate serotonin 
function in delay aversion. Possible explanations of the 
heterosis effect in the ADHD cases are presented. 
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Introduction 
The tendency to choose small-sooner over large delayed rewards 
is regarded as a signal marker of motivational dysfunction in 
ADHD (1). Effect sizes are moderate (Cohen’s d = .5 to .7 [2] 
with some between-study heterogeneity (e.g., [3] and [4] for 
non-significant findings). In a recent model this preference 
is explained as the product of two motivational components. 
The first component is an impulsive drive for immediate reward 
(IDIR; [1, 5]). IDIR manifests as a preference for small-
sooner rewards in choice experiments where trial length is the 
same irrespective of which of the two options is chosen. This 
is achieved experimentally by arranging a period of post-
reward delay (equal in length to the period of delay before 
the delayed-reward) after delivery of small-sooner rewards 
(i.e., a post reward delay condition). The second component is 
delay aversion which occurs when delay itself acquires a 
negative emotional valance, motivating actions allowing delay 
avoidance/escape. One model sees delay aversion as mediated by 
the experience of social censure associated with failures to 
perform effectively in delay settings in individuals with more 
fundamental IDIR-related deficits. In this model delay 
aversion exacerbates the effects of IDIR on small-sooner 
reward preference. Consistent with this formulation, in a 
recently reported choice delay experiment by Marco and 
colleagues, the preference for small-sooner rewards was 
significantly increased by removing the post-reward delay 
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period so that choice of small-sooner rewards reduced overall 
trial delay (i.e., a no post reward delay condition;6). The 
difference between choices for small-sooner rewards in the 
post reward and no post reward delay conditions (an index of 
delay aversion) was significantly greater for individuals with 
ADHD than controls (6).   
IDIR and delay aversion are postulated to be mediated by 
different brain systems. IDIR is hypothesized to be associated 
with dopamine function alterations within reward networks (7) 
that diminish signaling, and reduce the subjective value, of 
future rewards (8, 9). Consistent with this dopaminergic 
agents alter response to delayed reward in animal models (10), 
in healthy controls (11) and ADHD patients (12). Reward-
related effects in the ventral striatum, a key component of 
the brain’s reward circuits, are altered in both pre-clinical 
(13) and clinical ADHD studies (3, 14, 15). The 40–base pair 
VNTR polymorphism located in the 3`-untranslated region (3`-
UTR) of the DAT1 gene (SLC6A3; chromosome 5p15.3) contributes 
to the regulation of synaptic dopamine through altering its 
reuptake into pre-synaptic terminals. The DAT1 gene is 
differentially expressed in ventral striatum (16), and 
modulates reward-related activation there (17, 18) so that 
DAT1 genetic effects on impulsivity are thought to be 
moderated via alterations in reward circuits (18). Studies 
linking this polymorphism to ADHD give mixed results. Case-
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control and family association studies have shown inconsistent 
effects for the 10/10 genotype, and recent meta-analyses show 
significant but small effects(19, 20). 
In contrast, delay aversion, regarded as a specific 
example of a more general response to negatively valenced 
environmental stimuli or experiences (21, 22) is hypothesized 
to be mediated by amygdala activation (23) and modulated by 
serotonin function (24). Supporting the notion that delay is 
negatively valenced for ADHD patients, an attentional bias 
towards cues of delay, similar to the response of anxious 
individuals to cues of threat, has been reported (25). Plichta 
et al. (15) found delay-related hyper-activation in amygdala 
in ADHD in response to delayed rewards. Serotonin function has 
been implicated in impulsivity and immediate over delayed 
reward choices (26-30). The 5HTT, encoded by genetic locus 
SLC6A4 (chromosome 17q11.2), is a key regulator of serotonin 
function in the amygdala. Transcriptional activity of the gene 
is modified by a polymorphic regulatory region, commonly known 
as 5-HTTLPR. The short allele (“s”) of the 5-HTTLPR is 
associated with lower transcription and functional capacity of 
the 5HTT; (31, 32). The 5-HTTLPR promoter polymorphism appears 
to influence functional (33, 34) and structural (35, 36) 
properties of the amygdala, in particular in moderating the 
response to threatening and aversive stimuli (31, 37). We are 
not aware of any studies of the effect of the 5-HTTLPR in 
Sonuga-Barke et al. 
 
	   7	  
determining delayed reward choices. However, Aluja et al. (38) 
found that the s-allele was associated with impulsiveness in a 
prison sample, while Oades et al. (39) demonstrated a 
potential link between another polymorphism in 5HTT, the 
intron 2 VNTR, and cognitive impulsivity but not motivational 
impulsivity in ADHD. The 5HTT gene has also been implicated in 
ADHD (19, 40, 41), although a recent multi-centre study was 
negative in this regard (42). 
Here we test the hypothesis that IDIR and delay aversion 
will be differentially associated with polymorphisms in DAT1 
and 5HTT genes in a secondary analysis of the sub-sample of 
male children and adolescents with ADHD and their sex-matched 
siblings using the Maudsley Index of Delay Aversion (6) data 
from the Marco et al. study. Our specific predictions were 
that the 10R/10R genotype of the DAT1 VNTR will be related to 
IDIR and the s-allele of the 5HTT promoter polymorphism 
associated with delay aversion.  
Methods 
Participants 
Probands were from child psychiatry and specialist ADHD 
clinics in seven European countries (Belgium, Ireland, 
Germany, Spain, Switzerland, and UK) and Israel, and of 
European/Caucasian descent. The study was part of the 
neuropsychology component of the International Multi-centre 
ADHD Genetics (IMAGE) project (43). Each had a diagnosis DSM-
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IV ADHD-combined type and was between 6 and 16 years of age 
with at least one sibling in the same age range. The clinical 
diagnosis was validated against the Conners’ Rating Scales 
(44, 45) and the Parental Account of Children’s Symptoms 
(PACS; [46]) interview. Siblings were also screened for ADHD 
and if they met the inclusion threshold a PACS was 
administered in order to confirm the diagnosis. Exclusion 
criteria included pervasive developmental disorder, 
neurological diseases or other medical and genetic disorders. 
Parents gave written consent for the children to participate in 
the study. 
To simplify and strengthen the current analysis males only 
were included because; (i) the number of girls with relevant 
data was too small (Nprobands=35) to allow analysis of possible 
interactions between gender and genotype (e.g., only 18 
females probands with the relevant data carried the most 
common 10/10 DAT1 genotype compared to 168 male probands) and; 
(ii) there were markedly unequal male to female ratios for 
probands (35 v 285) compared to siblings (147 vs 158). MIDA 
data were available for 293 male probands (age range 6-16; 
mean= 10.78 years, sd= 2.61) and their 169 siblings (age range 
5-17; mean= 10.73, sd=2.98). Genotype data for the DAT1 VNTR 
were available for 288 probands and 162 siblings, and for 291 
probands and 168 siblings for the 5-HTTLPR. Seven cases with 
the DAT1 11-repeat allele were excluded from the analysis. 
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Thirty five siblings had a diagnosis of ADHD (total ADHD cases 
N=328) and were designated so for the current analyses.  
Tasks and measures 
Clinical Evaluation 
Symptom Rating Scales: Four scales were used to assess 
symptoms of ADHD and comorbid conditions: (the long versions 
of Conners’ Parent and Teacher Rating Scale and the parent and 
teacher Strengths and Difficulties Questionnaire (SDQ; 
[(47)]). 
Research Diagnosis: This was carried out using the revised 
PACS interview (46), the Conners’ parent and teacher rating 
scales and the SDQ. The PACS is a semi-structured interview 
used to collect parent-based detailed information on 
children’s behaviour. The interviewer asks parents to describe 
their child’s behaviour in different settings, and then rate 
the severity and frequency of the behaviour according to 
previously defined criteria. The settings are chosen to 
represent common unstructured (watching TV, reading or playing 
alone), semi-structured (meals, outings or shopping) and 
structured (home tasks, homework or getting ready) daily life 
situations. In this study, parents were asked to focus on 
examples of their children’s behaviour during the most recent 
medication-free period. A standardized diagnostic algorithm 
based on the DSM-IV criteria was applied to the information 
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from PACS and from the teacher rated ADHD subscale from 
Conners’ to derive a subtype diagnosis. In addition to the 
ADHD diagnosis, PACS also provides a Mood and an Anxiety score 
and a diagnosis of oppositional defiant disorder (ODD) based 
on the DSM-IV criteria. Previous studies have shown high 
inter-rater reliability (product-moment correlations between 
.76 and .96; [(46)]). The PACS has been validated against 
standardised questionnaires (such as the Conners` scale) used 
to assess ADHD (48). 
Intelligence: The vocabulary, similarities, picture completion 
and block designed subtests from the Wechsler Intelligence 
Scale for Children, 3rd edition (49) and the Wechsler 
Intelligence Scale for Adults, 3rd edition (50) were 
administered, and scores were prorated to provide a full 
estimate of IQ (51).  
IDIR and delay aversion: These were derived from the MIDA (6, 
52). The MIDA was one of three tests included in a battery 
implemented at eight IMAGE sites (see [53, 54] for description 
of the other two tasks). Participants were presented with a 
choice between small-sooner and large-delayed reward options 
in the context of a game-like space environment. Each trial 
involved a choice between firing at a single Cruiser that is 
presented first (the small-sooner option giving 1 point after 
2 seconds) and waiting to fire at two Cruisers that come later 
(the large delayed option giving 2 points after 30 seconds). 
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There were two conditions. In the no post reward delay 
condition, each trial followed on immediately after the 
participant had received their reward so that trial length was 
determined by the length of the pre-reward delay for the 
chosen option. In the post reward delay condition, the trial 
length was equalized for the two reward options by including a 
period of post-reward delay (2 seconds for the large-delayed 
option or 30 seconds for the small-sooner option). Under this 
condition the length of trial was always 32 seconds. (See 
Marco, et al. (6) for a more detailed description of 
instructions and rewards). Our index of IDIR was the 
percentage of small-sooner choices on post-reward delay trials 
when choosing this could not reduce overall trial delay – 
i.e., was not an expression of delay aversion. The delay 
aversion index was the difference between the percentage of 
small-sooner choices in the post reward delay condition and 
the no post reward delay condition (where choosing the small-
sooner reduces overall delay). For both IDIR and delay 
aversion high scores were more negative. Participants received 
instructions about the different options available in each 
condition.  
Genotyping  
DNA Extraction and Genotyping: DNA was extracted directly from 
blood samples or cell lines at Rutgers Cell line and DNA 
repository in the US. In a few cases we used a mouth swab 
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sampling technique and extracted the DNA at the SGDP 
laboratories in London. For genotyping of the VNTR markers we 
used a standard PCR method according to previous optimized 
protocols for the markers used in this study. For DAT1 we 
contrasted 9R/9R and 9R/10R with 10R/10R (we excluded those 
carrying the 11R allele). For 5-HTTLPR we compared s/s and s/l 
with l/l genotypes. We also determined an A/G SNP (rs25531) 
within the 5-HTTLPR repetitive element, the G-allele of which 
has been reported to render the l-allele transcriptionally 
less efficient (55). Genotyping for this was carried out at 
the Institute of Psychiatry and followed the protocol outlined 
in Wendland et al. (55), primers are available on request. 
Procedure 
The procedure for task administration is described in detail 
in Marco et al. (6). Families were required to withdraw ADHD 
medications for at least 48 hours before testing. The study 
had ethical approval from local site ethics committees.  
Analysis 
We tested whether the delay aversion and the IDIR data met 
normality assumptions. Delay aversion data were normally 
distributed. IDIR data were extremely skewed with the majority 
of cases (346; 54%) scoring zero. We therefore adopted 
different analytical approaches for the two outcomes. For both 
IDIR and delay aversion as the data were collected at 
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different sites and within families, we used mixed-effects 
regression models to account for the three-level nested 
structure (e.g., controlling for intra-familial sibling 
relationships). Delay aversion was introduced as a continuous 
variable. In a first step, the specific hypotheses were tested 
using a mixed-effects regression model for normally 
distributed outcomes, with delay aversion as the outcome, a 
contrast of the s-allele carriers versus the other genotypes 
as predictors, and random intercepts at the levels of site and 
family. All models included ADHD status and its interaction 
with genotype. In a second step, models were adjusted for age, 
IQ and ODD. As there was one extreme outlier in the data, we 
tested the models also after setting the outlier to the 95th 
percentile of the distribution (Winsorization) to prevent it 
from heavily influencing the statistical parameters. For IDIR 
(given its non-normal distribution) the outcome was 
dichotomised to represent zero vs non-zero IDIR. Mixed-effects 
logistic regression models for binary outcomes were used to 
test for associations of genotype and ADHD status with IDIR, 
with random effects and a second analytical step as described 
for the delay aversion model. The mixed-effects regression 
models were done using the Stata v11.1 commands xtmixed and 
xtmelogit, respectively.	  These models were also applied to the 
A/G SNP supplementary analyses. 
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Results 
Frequencies for common genotypes were as expected and in Hardy 
Weinberg Equilibrium: (DAT1: 9R/9R – N=27; 9R/10R – N=154; 
10/10 – N=267. 5-HTTLPR: s/s – N=87; s/l – N= 233; l/l – 
N=139). DAT1 and 5-HTTLPR genotypes were not significantly 
associated (χ2=1.77; ps>.70). IDIR and delay aversion were 
uncorrelated (r=.07; p>.10). Table 1 reports IDIR and delay 
aversion for genotypes by ADHD status.  
Primary analysis: First we tested the predicted associations 
(Figure 1). IDIR did not vary by DAT1 genotype (10/10 v 9/9 
and 9/10: χ2(1)=<0.01;p=.99). As predicted, 5-HTTLPR s-allele 
carriers were more delay averse than non-carriers (s/s & s/l v 
l/l: χ2(1)=4.57;p=.03). This effect was slightly stronger when 
analyses were conducted according to transcriptional activity 
status (.e. including SNP rs25531) - (“low activity” allele 
carriers being more delay averse than the “high/high” genotype 
(χ2(1)=5.37;p=.02; for delay aversion and IDIR by 
transcriptional genotype see supplementary information). There 
was a main effect of ADHD status on delay aversion 
(χ2(1)=5.93;p=.01; as originally found in Marco et al.(6)) but 
no interaction between genotype and ADHD (χ2(1)=2.77;p=.10; 
transcriptional activity groups - χ2(1)=0.64; p =.42). This 
pattern of significance did not change when IQ, ODD and age 
were added as covariates (effect of 5-HTTLPR s/s & s/l v l/l: 
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χ2(1) = 6.30;p = .01; effect of ADHD status: χ2(1) = 8.03; p 
= .005 ; Interaction between ADHD status and genotype: χ2(1) = 
3.02; p = .08), nor when outliers were Winsorized at the 95th 
percentile (value = -15).  
Exploratory analyses: Despite the lack of significant 
interaction, visual inspection of delay aversion means 
suggested a rather different pattern in probands and 
unaffected siblings by 5-HTTLPR genotype. To investigate this 
we conducted a set of exploratory post hoc analyses. These 
suggested that for the unaffected siblings there was a strong 
effect of the s-allele (χ2(1)=7.29;p=.01) with s/s and s/l 
having similar levels of delay aversion and both different 
from the l/l carriers, while for ADHD cases the effect was 
carried largely by the s/l genotype with heterozygotes being 
more delay averse than the homozygotes (χ2(1)=5.68;p=.02). 
Transcriptional activity status analysis gave the same pattern 
of results. For the unaffected siblings the “low/high” group 
being significantly more delay averse than the “high/high” 
group (χ2(1)=6.26;p=.04). For the affected siblings, the 
comparison of “low/high” with the “high/high” group missed 
statistical significance (χ2(1)=4.90;p=.09). These reduced 
levels of significance were likely related to the reduced 
number of participants for whom the rs25531 A/G SNP was 
available. Although not hypothesized, we also explored the 
associations between 5-HTTLPR and IDIR, and DAT1 and delay 
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aversion. There were no significant effects (5-HTTLPR and IDIR, 
traditional grouping: χ2(1)=0.65;p=.72; according to 
transcription activity: χ2(1)=0.76;p=.38 ; DAT1 VNTR and delay 
aversion: χ2(1)=0.94;p=.63).  
Discussion	  	  
The current results extend our understanding of different 
elements of impulsive choice, their genetic underpinnings and 
by extension their putative neurobiological basis. By 
providing evidence for differential genetic associations the 
results further validate the distinction between IDIR and 
delay aversion in models of impulsive choice (1). Using a 
hypothesis testing approach we predicted that IDIR (as 
measured by percentage of choices for the small-sooner reward 
in the post reward condition) would be associated with DAT1. 
This was based on the notion that IDIR is the result of 
altered signaling of delayed rewards modulated by dopamine 
function, which is affected by functional polymorphisms in the 
DAT1 gene. The result was negative and so the findings were at 
odds with the previous studies linking DAT1 genotype to 
impulsive choice, delayed responding (18), delay discounting 
and trait impulsivity (56). However bearing in mind the nature 
of the current sample it may be that effects of DAT1 on 
impulsive choice are sample specific and in particular may not 
underpin impulsive choice specifically in ADHD. The 10R allele 
may confer risk for ADHD only in combination with additional 
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DNA variants in the DAT1 gene. Thus, we had found that a 
specific haplotype of the DAT1 gene is associated with 
combined-type ADHD (57), replicating a previous report from a 
different sample (58); additional DAT1 genetic variants from 
the 5’ region of the gene have also been reported to be 
associated with ADHD (59). In general, it has been difficult 
to identify robust and consistent associations between 
specific dopamine genotypes, including DAT1 and putative 
neuropsychological endophenotypes (60). The current result 
therefore adds to this rather fragmented picture, although it 
is not possible, of course, to rule out the effects of 
variations in dopamine genes, other than DAT1, involved in 
dopamine neurotransmission on IDIR.  
 Our second hypothesis was that delay aversion (the 
additional effect of linking small-sooner reward choices to 
delay reduction) would be associated with 5-HTTLPR genotype. 
This was based on the view that delay aversion was a specific 
case of a more general avoidant response to aversive events 
and therefore would be mediated by similar neurobiological 
mechanisms linked to serotonin function (34). As predicted, 5-
HTTLPR genotype was associated with delay aversion with s-
allele carriers more delay averse than non-carriers. This 
finding should be interpreted in relation to a more general 
link between 5-HTTLPR and impulsive choice seen in tryptophan 
depletion studies suggesting serotonin status affects waiting 
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behavior and delay-related choice in other populations (26, 
34, 61). However, it presents the first study to extend this 
to the effects of 5-HTTLPR genotype on impulsive choice 
behavior on laboratory tasks. It also represents one of the 
first studies implicating this genotype in ADHD 
neuropsychology.  
Although not ideally placed to explore the moderation of 
these effects by ADHD status given the familial relations 
between affected and unaffected cases we conducted separate 
exploratory analyses for these groups. This confirmed the 
observation of a rather different pattern of results for the 
two groups and an unexpected heterosis effect in the ADHD 
group (the s/l group being the most delay averse). This raises 
the possibility that 5-HTTLPR genotype effects on impulsive 
behaviour may be dependent on disorder status or more 
generally on participant characteristics. This possibility has 
not been investigated systematically as most studies of 5-
HTTLPR s-allele effects on amygdala reactivity have typically 
been in samples of healthy volunteers with no history of 
affective or other psychiatric disorders.   
Although most studies have not specifically tested for 
it, a number of studies have found group-specific evidence of 
molecular heterosis at the 5HTT gene. Heterozygote subjects 
have shown lower [I125]beta-citalopram serotonin transporter 
binding in cocaine users (62), increased white-matter lesions 
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among depressed patients (63), higher cognitive function in 
elderly adults (64) and lower availability of central 5HTT 
(16). In a recent study, Malmberg et al. (65) found 
associations between disruptive behaviour disorder and s/l 
genotype. Explanations for these effects include; (i) an 
inverted U-shaped response curve in which either too little or 
too much gene expression is deleterious; (ii) an independent 
third factor causing a hidden stratification of the sample 
such that both the two homozygote genotype (s/s and l/l) are 
independently associated with the highest phenotype score 
relative to the heterozygote (e.g., s/l); (iii) greater 
fitness in heterozygotes because they show a broader range of 
gene expression than both homozygotes (for a review see 
[(66)]). Clearly, although intriguing, our finding showing a 
disorder specific heterosis effect in families with ADHD 
children needs to be confirmed in other large independent 
samples with non-related controls.  
The current results may take us further in understanding 
heterogeneity in ADHD. Previous studies (6) found that only a 
sub-set of ADHD children show impulsive responding on the 
MIDA. This may therefore be a marker of a sub-type of ADHD in 
which 5-HTTLPR polymorphisms play a particularly important 
role in the pathogenesis of the condition. This may explain 
the inconsistency in results relating to the association 
between ADHD and this genotype. The expectation is that 
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effects would be larger for 5-HTTLPR genotypes in a refined 
delay averse sample of ADHD children. If this were the case it 
may be possible to isolate a sub-group whose ADHD is mediated 
by delay averse and might respond to serotonergic drugs (39) 
as a component of their treatment on the one hand or delay 
training on the other (25). The results of Zepf et al. (67) 
demonstrating that ADHD children with comorbid anxious-
depression and/or aggression were sensitive to tryptophan 
depletion, highlights the possibility that a delay averse sub-
group might be more likely to have these comorbidities.  
The current study had many strengths. These included the 
large sample and the use of an experimental paradigm to 
dissect different elements of impulsive choice; however, there 
were a number of limitations. First, the skewed distribution 
of the IDIR measure and the need to dichotomize it for the 
analysis rather than use it as a continuous measure might have 
reduced its sensitivity compared with the delay aversion 
measure, the negative finding therefore needs to be 
interpreted with caution, although the effects were very far 
from significant. Second, the study did not include direct 
measures or manipulations of serotonin or dopamine levels 
which would have helped resolve issues around the functional 
significance of the different allelic combinations. Third, 
there were insufficient affected girls in this subset of the 
IMAGE sample to provide power to include gender as a factor in 
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the analysis. Finally, the current sample with genotypic 
information did not include unrelated controls – this means 
that it remains uncertain how specific the role of these 
genotypes might be to ADHD because of the familial link and 
associated genetic overlap between probands and their 
unaffected sibs. Future studies should include biologically 
unrelated controls and groups of patients with other disorders 
to examine this issue. 
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Table	  1 
 DAT1 VNTR 5-HTTLPR 
 9/9 9/10 10/10 s/s s/l l/l 
IDIR        
ADHD 45.00 50.73 50.93 53.95  46.99 54.39 
none 37.50 40.86 38.26 27.78  46.81 34.29 
Delay 
Aversion 
      
ADHD 6.15 
(20.41) 
12.16 
(24.05) 
12.75 
(24.98) 
7.87 
(21.76) 
15.71 
(27.50) 
11.40 
(22.16) 
none 12.52 
(21.47) 
8.53 
(23.39) 
10.70 
(24.62) 
11.42 
(20.67) 
10.98 
(23.94) 
2.52 
(22.14) 
	  
Table 1: The relationship between impulsive drive for 
immediate reward (IDIR) and delay aversion and genotype as a 
function of ADHD status.  
NB: IDIR – Impulsive Drive for Immediate Reward represents the 
proportion of individuals who chose the small-sooner reward on 
all trials in the post reward delay condition Delay aversion 
was based on the difference between the proportion of choices 
made for the smaller sooner reward in post-reward and no post 
reward delay condition. Higher scores indicate more small-
sooner choices. Figures in parentheses are standard 
deviations.	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Figure legends:	  
	  
Figure 1: The mean level of MIDA delay aversion as a function 
of 5-HTTLPR status for the combined s/s and s/l genotype groups 
compared with the l/l group. Note: Delay aversion is 
calculated as the difference in percentage choices of the 
small-sooner option under no post reward and post reward delay 
conditions. Higher scores mean more delay aversion.	  
	  
Figure 2: IDIR levels as a function of DAT1 VNTR genotype with 
the combined 9/9 and 9/10 groups compared to the 10/10 group. 
Note: IDIR=Impulsive Drive for Immediate Reward represents the 
proportion of individuals who chose the small-sooner reward on 
all trials in the post reward delay condition.	  
